SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intuition is the L2 for trusted data, and the world's first token-curated graph—allowing people and machines to get the information they need, when they need it, from the sources they trust. With Intuition, you can put your 'intuition' to work—transforming your thoughts, opinions, and experiences into fuel for personalized AI, recommendations, and ads that truly understand you. You fully control your digital identity and data—the most valuable resources of the digital age—enabling you to fully leverage their value while unlocking and democratizing trillions in economic potential. Bring your social graphs, preferences, and 'intuition' with you wherever you go. No more rebuilding your profile and connections from scratch on every new platform—create and curate a universal, portable identity and context that allows applications and AI across the web to understand you instantly. And as you contribute, you’re not just improving your own experience—you’re enhancing the web for everyone who follows and trusts your perspective.

Trust Community Token

Trust Community Token ($TRUST) is trending as traders discuss potential 'round 2' opportunities and consolidation patterns, while also mentioning a prior selloff. The community is actively discussing entry and exit points, with some comparing it to other tokens and suggesting profit-taking strategies in other crypto.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is trending due to its acquisition of Astria Therapeutics, which aims to strengthen its position in the hereditary angioedema market; however, some investors are expressing concerns about the deal's value and potential impact on shareholder returns. The community is actively debating the long-term implications of this strategic move amidst existing discussions on the company's financial performance and future growth prospects. Short interest remains high as well.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.

ASP Isotopes Inc

ASPI is trending as the community discusses a recently announced private placement in its spin-off, Quantum Leap Energy (QLE), with notable investors including the Trump brothers. This news has sparked excitement about potential catalysts and a broader discussion on the company's prospects in the nuclear and medical isotope industries. Some investors also point to upcoming catalysts including the finalization of the Renergen deal and the QLE spin-off.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending amid discussions about its potential bottom and future growth prospects, with some seeing it as a long-term investment, while others express concerns over valuation and broader economic headwinds affecting the restaurant sector. Community members are weighing bullish sentiments against potential short-term challenges and comparing CAVA's performance and positioning relative to competitors like Chipotle. Recent options activity suggests traders are positioning for potential volatility.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead Sciences is trending due to FDA approval of Yeztugo, a twice-yearly injectable for HIV prevention, bolstering its strong HIV portfolio. While the approval is considered an "expected positive," the community is debating the drug's pricing, potential market impact, and how it will influence the company's overall growth amid competition. There is speculation around how insurance coverage and potential cannibalization of existing treatments may affect Gilead's financials.

Pegasystems, Inc. engages in the development, market, license, and support of software, which allows organizations to build, deploy, and change enterprise applications. Its product, Pega Infinity, helps connect enterprises to their customers in real-time across channels, streamline business operations, and adapt to meet changing requirements. The company was founded by Alan Trefler in 1983 and is headquartered in Waltham, MA.

Pegasystems Inc.

PEGA is trending due to positive sentiment around its AI-driven capabilities and potential, with Wedbush reiterating an outperform rating. Community members are discussing options strategies and anticipating further price increases. The stock is also gaining attention as a potential AI sector play, with analysts highlighting its unique approach to providing AI tools for enterprises.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is trending as investors weigh its growth prospects against recent developments. Community discussions revolve around its platform strategy, potential AI security advancements, and comparisons to competitors like CrowdStrike. Analyst ratings are mixed, with some highlighting its growth potential and others expressing concerns about valuation.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending following news that the U.S. Department of Commerce is using the platform to deliver economic data on-chain. The community is discussing potential integrations with other platforms and anticipating a potential price surge. Some are comparing it to other crypto assets and suggesting it as the next big runner in the Real World Asset (RWA) space.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community speculates on potential ETF inflows and a possible market rebound. Conversations revolve around identifying the bottom and whether now is the time to buy, while some traders are comparing it to other meme coins. There's also discussion around Dogecoin's potential integration with X payments.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is trending as traders discuss potential market directions, reacting to factors like expectations around rate cuts and AI's influence following mixed earnings. Community members are actively sharing options strategies and debating entry and exit points, while some express concerns about a potential AI bubble. Discussions also address the impact of trade tensions and technical indicators.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NEW YORK, Nov. 13, 2025 /PRNewswire/ -- <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4556462-1&amp;h=2223829268&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=Tradr+ETFs">Tradr ETFs</a>,&nbsp;a provider of ETFs designed for sophisticated investors and professional traders, today launched four new single stock leveraged ETFs. The funds seek to deliver twice (200%) the daily performance of a specific underlying stock. Listed on Cboe, these ETFs are the first and only strategies available for this group of growth-oriented companies.The following ETFs are expected to open for trading today:<ul><li>Tradr 2X Long BE Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4556462-1&amp;h=678802382&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Fbex&amp;a=BEX">BEX</a>) – tracks Bloom Energy Corp. (NYSE: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-launches-leveraged-etfs-on-bloom-energy-celestica-nano-nuclear--synopsys-302613005.html#financial-modal">BE</a>)</li><li>Tradr 2X Long CLS Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4556462-1&amp;h=3595558559&amp;u=https%3A%2F%2Fwww.tradretfs.com%2Fcsex&amp;a=CSEX">CSEX</a>) – tracks Celestica Inc. (Nasdaq: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-launches-leveraged-etfs-on-bloom-energy-celestica-nano-nuclear--synopsys-302613005.html#financial-modal">CLS</a>)</li><li>Tradr 2X Long NNE Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4556462-1&amp;h=2182584633&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Fnnex&amp;a=NNEX">NNEX</a>) – tracks NANO Nuclear Energy Inc. (Nasdaq: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-launches-leveraged-etfs-on-bloom-energy-celestica-nano-nuclear--synopsys-302613005.html#financial-modal">NNE</a>)</li><li>Tradr 2X Long SNPS Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4556462-1&amp;h=1643873749&amp;u=https%3A%2F%2Fwww.tradretfs.com%2Fsnpx&amp;a=SNPX">SNPX</a>) – tracks Synopsys Inc. (Nasdaq: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-launches-leveraged-etfs-on-bloom-energy-celestica-nano-nuclear--synopsys-302613005.html#financial-modal">SNPS</a>)</li></ul>"Although they are involved in different industries, these four underlying stocks are all tied to a prevalent theme: building and supporting the AI infrastructure that will be necessary to meet America's demand for compute power," said Matt Markiewicz, Head of Product and Capital Markets at Tradr ETFs. "With this launch, the Tradr suite of leveraged ETFs now has more than fifty strategies, which is a remarkable accomplishment considering we started with just seven this April. We are grateful to our investors, the 'Tradr Tribe', and our partners for their trust and enduring support."In 2022, Tradr ETFs became the first issuer to launch leveraged ETFs on single stocks, starting with TSLQ for Tesla and NVDS for Nvidia. With today's listings, Tradr's lineup has grown to 53 leveraged ETFs representing over $2 billion in assets under management. Tradr's strategies can be accessed through most brokerage platforms and allow investors to avoid the hassle of using margin and the complexity of options trading. The firm continues its mission of providing sophisticated investors with innovative trading tools that enhance their ability to express market views with precision and efficiency.For detailed information on Tradr ETFs and the significant risks involved with leveraged ETFs, please visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4556462-1&amp;h=910640517&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=www.tradretfs.com">www.tradretfs.com</a>.About Tradr ETFs <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4556462-1&amp;h=2223829268&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=Tradr+ETFs">Tradr ETFs</a>&nbsp;are designed for sophisticated investors and professional traders&nbsp;who are looking to express high conviction investment views. The strategies include leveraged and inverse ETFs that seek short or long exposure to actively traded stocks and ETFs.IMPORTANT RISK INFORMATIONTradr ETFs are for sophisticated investors and professional traders with high conviction views and are very different from most other ETFs. The Funds are intended to be used as short-term trading vehicles and pursue leveraged investment objectives, which means they are riskier than alternatives that do not use leverage because the Funds magnify the performance of their underlying security. The volatility of the underlying security may affect a Fund's return as much as, or more than, the return of the underlying security.Investors in the fund should: (a) understand the risks associated with the use of leverage; (b) understand the consequences of seeking inverse and leveraged investment results; (c) for short ETFs, understand the risk of shorting; (d) intend to actively monitor and manage their investment. Fund performance will likely be significantly different than the benchmark over periods longer than the specified reset period and the performance may trend in the opposite direction than its benchmark over periods other than that period.Leverage increases the risk of a total loss of an investor's investment, may increase the volatility of the Funds, and may magnify any differences between the performance of the Funds and their reference security. The Funds seek leveraged investment results for a specific period (daily, monthly or quarterly). The exact exposure of an investment in the Fund intra-period will depend upon the movement of the reference security from the end of the prior period until the time of investment by the investor.The Fund will not attempt to position its portfolio to ensure it does not gain or lose more than a maximum percentage of its net asset value on a given trading day. As a consequence, investors in a Fund that seeks two times daily performance would lose all of their money if the Fund's underlying security moves more than 50% in a direction adverse to the Fund on a given trading day.ETFs involve risk including possible loss of the full principal value. There is no assurance that the Fund will achieve its investment objective. Principal risks and other important risks may be found in the prospectus. Past performance does not guarantee future results.ETF shares are bought and sold at market price (not NAV) and are not individually redeemed from the ETF. There can be no guarantee that an active trading market for ETF shares will develop or be maintained, or that their listing will continue or remain unchanged. Buying or selling ETF shares on an exchange may require the payment of brokerage commissions and frequent trading may incur brokerage costs that detract significantly from investment returns.Investors should carefully consider the investment objectives, risks, charges and expenses of the Funds. This and other important information about the Fund is contained in the Prospectus, which can be obtained by visiting <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4556462-1&amp;h=910640517&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=www.tradretfs.com">www.tradretfs.com</a> . The Prospectus should be read carefully before investing.Distributed by ALPS Distributors, Inc, which is not affiliated with AXS Investments or its Tradr ETFs. AXI000790SOURCE Tradr ETFsNote: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Tradr Launches Leveraged ETFs on Bloom Energy, Celestica, NANO Nuclear & Synopsys

First-to-market funds seek to provide 200% long exposure on exciting growth stories

Others

Synaptogenix Announces $5.0 Million Financing

Synaptogenix Announces $5.0 Million Financing Synaptogenix Announces $5.0 Million Financing PR Newswire NEW YORK, Sept. 11, 2024 NEW YORK, Sept. 11, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq...

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury Synaptogenix Announces New Collaboration with LSU Health New Orleans for...

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial...

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and...

Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics

Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery...

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing PR Newswire NEW YORK, April 3, 2024 Common stock will begin...

Synaptogenix implementing reverse stock split to maintain Nasdaq listing

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Synaptogenix, Inc. (NASDAQ:SNPX) Short Interest Update

Synaptogenix, Inc. (NASDAQ:SNPX - Get Free Report) was the target of a significant decline in short interest in March. As of March 15th, there was short interest totalling 426,600 shares, a decline...

SNPX
Tradr 2X Long SNPS Daily ETF

Feed

News

Sentiment

Fundamentals

Info

Latest SNPX News

SNPXTradr 2X Long SNPS Daily ETF